A common question from patients considering TMS: if antidepressants haven't worked, why would a different kind of brain treatment work? The answer lies in mechanism — and the clinical evidence supporting TMS in the treatment-resistant population is substantial.
The Mechanism Difference Is Fundamental
Antidepressants work systemically. They enter the bloodstream and modify neurotransmitter availability — primarily serotonin, norepinephrine, and dopamine — across the entire brain and body. This systemic approach is effective for a significant proportion of patients, but it has a ceiling: when a patient's depression is driven by circuit-level dysfunction rather than neurochemical imbalance alone, adjusting neurochemistry does not address the underlying driver.
TMS bypasses the circulatory system entirely. It acts directly on the neurons of the left dorsolateral prefrontal cortex — the specific region that is measurably hypoactive in a large proportion of depressed patients — using precisely targeted magnetic pulses to stimulate those neurons directly and promote neuroplasticity through repetition.
Antidepressants: systemic neurochemistry adjustment. TMS: direct, local magnetic stimulation of the specific brain circuit underactive in depression. Different targets. Different mechanisms. Different patient populations where each excels.
What the Clinical Data Shows
The FDA pivotal trial that secured NeuroStar's 2008 clearance enrolled patients who had failed at least one antidepressant trial — the treatment-resistant population. The trial was a multi-site, randomized, sham-controlled study. Results: 58% of active TMS patients achieved clinically meaningful response vs. 37% of sham patients (a statistically significant difference, p<0.05), and approximately 30% achieved full remission.
Critically, the FDA trial data and subsequent real-world registry data both show that TMS response rates do not diminish substantially with the number of prior medication failures — unlike successive antidepressant trials, where each failure is associated with lower probability of the next medication working.
Side Effect Profiles: A Stark Contrast
This is where the comparison becomes most clinically meaningful for patients. Antidepressants carry well-documented systemic side effects: weight gain (30–40% of patients), sexual dysfunction (30–40%), cognitive blunting, nausea, sleep disruption, and discontinuation syndrome on cessation. These side effects cause an estimated 30–40% of patients to discontinue medication before achieving adequate response — dramatically reducing real-world effectiveness.
TMS side effects are localized and temporary: scalp discomfort or headache during early sessions, which resolves within the first week in virtually all patients. No weight effects. No sexual effects. No cognitive effects. No withdrawal.
When Antidepressants Are Still Preferred
TMS is not appropriate for every patient. Antidepressants remain the first-line treatment for MDD due to accessibility, lower cost, and strong evidence. For patients who respond adequately to medication and tolerate it well, continuing pharmacotherapy is typically the right choice. TMS is most clearly indicated after medication has not provided adequate relief — and this is the patient population where the evidence for TMS is strongest.
TMS is also fully compatible with continued antidepressant use — many patients use TMS alongside existing medications, with some subsequently reducing medication burden under physician guidance after responding to TMS.